Download from app store
We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
story of the week
Published in Cardiology

Journal Scan / Research · November 09, 2023

Mavacamten in Patients With HCM Referred for Septal Reduction: Week 56 Results

JAMA Cardiology


Additional Info

Disclosure statements are available on the authors' profiles:

JAMA Cardiology
Mavacamten in Patients With Hypertrophic Cardiomyopathy Referred for Septal Reduction: Week 56 Results From the VALOR-HCM Randomized Clinical Trial
JAMA Cardiol 2023 Oct 01;8(10)968-977, MY Desai, A Owens, K Wolski, JB Geske, S Saberi, A Wang, M Sherrid, PC Cremer, NK Lakdawala, A Tower-Rader, D Fermin, SS Naidu, NG Smedira, H Schaff, E McErlean, C Sewell, L Mudarris, Z Gong, K Lampl, AJ Sehnert, SE Nissen

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading